Turnstone Biologics Appoints William Waddill to its Board of Directors

Core Insights - Turnstone Biologics Corp. has appointed William Waddill to its Board of Directors, effective April 15, 2024, while Patrick Machado has stepped down from the Board [1][2] Group 1: Leadership Changes - William Waddill brings over 30 years of financial and operational expertise in the biotechnology sector and has held leadership roles in various organizations [2][3] - Patrick Machado has been recognized for his significant contributions to Turnstone over nearly six years [2] Group 2: Company Overview - Turnstone Biologics is focused on developing a novel Selected tumor-infiltrating lymphocyte (TIL) therapy aimed at treating solid tumors [4] - The company's lead clinical program, TIDAL-01, is currently in multiple Phase 1 studies targeting various cancers, including colorectal cancer and melanoma [4]